Moderator: Larus S. Gudmundsson (he/him/his) – University of Iceland
Moderator: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
Speaker: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.
Speaker: Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland
Speaker: Menno van der Elst (he/him/his) – Dutch Medicines Evaluation Board
Plenary
Moderator: Larus S. Gudmundsson (he/him/his) – University of Iceland
### he/him/his @@@ Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety ### 1061393###Moderator###Distinguished Professor###University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety###Moderator: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
### @@@ Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland. ### 1900347###Speaker###Professor, University of Iceland; Chief Physician, Landspitali University Hospital.###Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.###Speaker: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.
### he/him/his @@@ Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland ### 1901666###Speaker###Chief Epidemiologist###Directorate of Health Iceland###Speaker: Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland
### she/her/hers @@@ Menno van der Elst (he/him/his) – Dutch Medicines Evaluation Board ### 1901668###Speaker###Member###Dutch Medicines Evaluation Board###Speaker: Menno van der Elst (he/him/his) – Dutch Medicines Evaluation Board
### he/him/hisModerator: Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
Moderator: Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research
Speaker: Anne M. Butler, PhD, MS – Washington University School of Medicine
Speaker: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen
Plenary
Moderator: Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
### she/her/hers @@@ Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research ### 1046831###Moderator###Professor and Director###Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research###Moderator: Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research
### he/him/his @@@ Anne M. Butler, PhD, MS – Washington University School of Medicine ### 1062638###Speaker###Assistant Professor###Washington University School of Medicine###Speaker: Anne M. Butler, PhD, MS – Washington University School of Medicine
### @@@ Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University ### 1062566###Speaker###Assistant Professor###McGill University###Speaker: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
### he/him/his @@@ Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen ### 1302750###Speaker###Professor###Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen###Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen
###Moderator: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
Moderator: Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida
Women and off-spring
Moderator: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
Moderator: Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida
Women and off-spring
Moderator: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
### @@@ Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida ### 1063291###Moderator###PhD Student###University of Florida###Moderator: Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida
### he/him/hisPresenting Author: Qi Zhang, MSPH (she/her/hers) – Department of Epidemiology, Emory University
Author: Michael Goodman, MD, MPH (he/him/his) – Emory University
Databases
Presenting Author: Qi Zhang, MSPH (she/her/hers) – Department of Epidemiology, Emory University
### she/her/hers @@@ Michael Goodman, MD, MPH (he/him/his) – Emory University ### 1900258###Author###Professor###Emory University###Author: Michael Goodman, MD, MPH (he/him/his) – Emory University
### he/him/hisPresenting Author: Julie Barberio (she/her/hers) – Department of Epidemiology, Emory University
Author: Rohini K. Hernandez, PhD MPH (she/her/hers) – Amgen, Inc.
Author: Ashley I. Naimi, PhD – Department of Epidemiology, Emory University
Author: Rachel E. Patzer, PhD – Department of Epidemiology, Emory University
Author: Christopher Kim, PhD – Center for Observational Research, Amgen Inc.
Author: Timothy L. Lash, DSc – Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA
Databases
Presenting Author: Julie Barberio (she/her/hers) – Department of Epidemiology, Emory University
### she/her/hers @@@ Rohini K. Hernandez, PhD MPH (she/her/hers) – Amgen, Inc. ### 1088313###Author###Director of Observational Research###Amgen, Inc.###Author: Rohini K. Hernandez, PhD MPH (she/her/hers) – Amgen, Inc.
### she/her/hers @@@ Ashley I. Naimi, PhD – Department of Epidemiology, Emory University ### 1655283###Author###Associate Professor###Department of Epidemiology, Emory University###Author: Ashley I. Naimi, PhD – Department of Epidemiology, Emory University
### @@@ Rachel E. Patzer, PhD – Department of Epidemiology, Emory University ### 1655284###Author###Professor###Department of Epidemiology, Emory University###Author: Rachel E. Patzer, PhD – Department of Epidemiology, Emory University
### @@@ Christopher Kim, PhD – Center for Observational Research, Amgen Inc. ### 1900271###Author###Director###Center for Observational Research, Amgen Inc.###Author: Christopher Kim, PhD – Center for Observational Research, Amgen Inc.
### @@@ Timothy L. Lash, DSc – Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA ### 1358745###Author###Professor and Chair###Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA###Author: Timothy L. Lash, DSc – Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA
###Presenting Author: Emeline Maisonneuve, MD (she/her/hers) – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
Author: Eva Gerbier – Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Author: Fatima Tauqeer – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway
Author: Léo Pomar, PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Author: Guillaume Favre, MD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Author: Ursula Winterfeld, PhD – Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Author: Anneke Passier, PhD – Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands
Author: Alison Oliver, PhD – UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK
Author: David Baud, MD PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Author: Michael Ceulemans, PhD – Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
Author: Alice Panchaud, PhD – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
Vaccines
Presenting Author: Emeline Maisonneuve, MD (she/her/hers) – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
### she/her/hers @@@ Eva Gerbier – Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359620###Author###PhD student###Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: Eva Gerbier – Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Fatima Tauqeer – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway ### 1063106###Author###PhD student###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway###Author: Fatima Tauqeer – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway
### @@@ Léo Pomar, PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1659156###Author###Midwife and Professor###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: Léo Pomar, PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Guillaume Favre, MD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1659150###Author###PhD student###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: Guillaume Favre, MD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Ursula Winterfeld, PhD – Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359633###Author###Pharmacist###Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: Ursula Winterfeld, PhD – Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Anneke Passier, PhD – Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands ### 1900305###Author###Teratology information specialist###Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands###Author: Anneke Passier, PhD – Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands
### @@@ Alison Oliver, PhD – UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK ### 1900306###Author###Senior Medical Information Scientist###UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK###Author: Alison Oliver, PhD – UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK
### @@@ David Baud, MD PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359631###Author###Head of department###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: David Baud, MD PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Michael Ceulemans, PhD – Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium ### 1900303###Author###Pharmacist and researcher###Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium###Author: Michael Ceulemans, PhD – Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
### @@@ Alice Panchaud, PhD – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland ### 1900290###Author###Head of BIHAM Pharmacy###Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland###Author: Alice Panchaud, PhD – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
###Presenting Author: Anna-Belle Beau, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, Toulouse, France
Author: Xavier Moisset – Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand
Author: Justine Benevent – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Author: Marie Beslay, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France.
Author: Claudia C. Bartolini – ARS Toscana
Author: Marie-Agnès Bernard – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France
Author: Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy
Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
Author: Sue Jordan, MB.BCh., PhD. PGCE (FE), – Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea
Author: Régis Lassalle, MSc – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France
Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Author: Marco Manfrini – Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy
Author: Visa Martikainen – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
Author: Joan K. Morris – St George's, University of London, London
Author: Amanda j. Neville, N/A – Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy
Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Author: Olga Paoletti – Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy
Author: Jingping Mo – Worldwide Medical and Safety, Pfizer Inc., New York, NY
Author: Christine Damase-Michel, PhD, PharmD – Université Toulouse III
Medications in Pregnancy & Lactation (MiPaL)
Presenting Author: Anna-Belle Beau, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, Toulouse, France
### @@@ Xavier Moisset – Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand ### 1900353###Author###Medical Doctor###Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand###Author: Xavier Moisset – Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand
### @@@ Justine Benevent – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1900337###Author###Researcher###PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Justine Benevent – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Marie Beslay, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France. ### 1900336###Author###Postdoctoral researcher###Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France.###Author: Marie Beslay, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France.
### @@@ Claudia C. Bartolini – ARS Toscana ### 1063227###Author###Researcher###ARS Toscana###Author: Claudia C. Bartolini – ARS Toscana
### @@@ Marie-Agnès Bernard – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France ### 1658844###Author###Statistician###Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France###Author: Marie-Agnès Bernard – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France
### @@@ Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy ### 1302758###Author###Head of Unit at ARS Toscana, Florence, Italy###ARS Toscana, Florence, Italy###Author: Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy
### she/her/hers @@@ Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki ### 1360036###Author###Professor###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki###Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
### @@@ Sue Jordan, MB.BCh., PhD. PGCE (FE), – Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea ### 1359730###Author###professor###Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea###Author: Sue Jordan, MB.BCh., PhD. PGCE (FE), – Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea
### @@@ Régis Lassalle, MSc – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France ### 1358268###Author###Head of Statistics and Data management###Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France###Author: Régis Lassalle, MSc – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France
### @@@ Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1358190###Author###Associate professor###Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1063068###Author###Associate Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Marco Manfrini – Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy ### 1900338###Author###Specialist in health statistics and biometrics###Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy###Author: Marco Manfrini – Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy
### @@@ Visa Martikainen – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1359729###Author###Data manager, statistician###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###Author: Visa Martikainen – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Joan K. Morris – St George's, University of London, London ### 1900343###Author###Professor###St George's, University of London, London###Author: Joan K. Morris – St George's, University of London, London
### @@@ Amanda j. Neville, N/A – Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy ### 1359720###Author###Registry Leader, IMER Registry###Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy###Author: Amanda j. Neville, N/A – Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Olga Paoletti – Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy ### 1359270###Author###Researcher###Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy###Author: Olga Paoletti – Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy
### @@@ Jingping Mo – Worldwide Medical and Safety, Pfizer Inc., New York, NY ### 1358153###Author###Professor###Worldwide Medical and Safety, Pfizer Inc., New York, NY###Author: Jingping Mo – Worldwide Medical and Safety, Pfizer Inc., New York, NY
### @@@ Christine Damase-Michel, PhD, PharmD – Université Toulouse III ### 1358255###Author###Associate Professor in Pharmacology###Université Toulouse III###Author: Christine Damase-Michel, PhD, PharmD – Université Toulouse III
###Presenting Author: Milica Zugic, MScPharm – Department of Pharmacy, University of Oslo, Oslo, Norway
Author: Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo
Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Medications in Pregnancy & Lactation (MiPaL)
Presenting Author: Milica Zugic, MScPharm – Department of Pharmacy, University of Oslo, Oslo, Norway
### @@@ Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo ### 1655801###Author###Postdoctoral Fellow###PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo###Author: Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1063068###Author###Associate Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
###Presenting Author: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
Author: Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
Author: Vidar Hjellvik, PhD – Norwegian Institute of Public Health
Author: Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
Author: Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway
Author: Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
Author: Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales
Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
Author: Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
Author: Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Author: Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health
Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
Author: Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
Author: Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
Author: Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
Author: Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
Author: Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health
Author: Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
Author: Helga Zoega – University of New South Wales - Sydney
Medications in Pregnancy & Lactation (MiPaL)
Presenting Author: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet ### 1062759###Author###Researcher###Centre for Pharmacoepidemiology, Karolinska Institutet###Author: Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
### @@@ Vidar Hjellvik, PhD – Norwegian Institute of Public Health ### 1358617###Author###Statistician###Norwegian Institute of Public Health###Author: Vidar Hjellvik, PhD – Norwegian Institute of Public Health
### @@@ Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1360037###Author###Biostatistician###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### she/her/hers @@@ Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway ### 1360035###Author###Professor, consultant neurologist###NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway###Author: Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway
### @@@ Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1062595###Author###PhD candidate###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### @@@ Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales ### 1359563###Author###Senior Biostatistician###School of Population Health, University of New South Wales###Author: Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales
### he/him/his @@@ Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki ### 1360036###Author###Professor###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki###Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
### @@@ Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia ### 1358233###Author###Senior Research Fellow###National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia###Author: Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
### she/her/hers @@@ Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden ### 1360225###Author###Statistician###Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden###Author: Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
### he/him/his @@@ Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health ### 1358431###Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health###Author: Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health
### @@@ Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1358190###Author###Associate professor###Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1063034###Author###Chief physician, professor###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### @@@ Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia ### 1358403###Author###Professor###School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia###Author: Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
### @@@ Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet ### 1358377###Author###Associate professor###Centre for Pharmacoepidemiology, Karolinska Institutet###Author: Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
### @@@ Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1659382###Author###Statistician###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###Author: Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### @@@ Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health ### 1063219###Author###Senior researcher###Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health###Author: Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health
### @@@ Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1900239###Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###Author: Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Helga Zoega – University of New South Wales - Sydney ### 1358124###Author###Associate professor/professor###University of New South Wales - Sydney###Author: Helga Zoega – University of New South Wales - Sydney
###Moderator: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
Moderator: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
Cardiovascular medications and outcomes
Moderator: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
Moderator: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
Cardiovascular medications and outcomes
Moderator: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
### she/her/hers @@@ Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University ### 1062566###Moderator###Assistant Professor###McGill University###Moderator: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
### he/him/hisPresenting Author: Victoria A. Fuchs – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
Author: Anne Spinewine – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium
Author: Séverine Henrard – 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
Adherence
Presenting Author: Victoria A. Fuchs – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
### @@@ Anne Spinewine – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium ### 1900256###Author###Full professor###1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium###Author: Anne Spinewine – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium
### @@@ Séverine Henrard – 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium ### 1900257###Author###Associate professor###1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium###Author: Séverine Henrard – 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
###Presenting Author: Courtney A. Johnson, MPH (she/her/hers) – Brown University
Author: Theresa I. Shireman, PhD (she/her/hers) – Brown University
Author: Amal N. Trivedi, MD, MPH – Brown University
Author: Omar Galárraga, PhD (he/him/his) – Brown University
Adherence
Presenting Author: Courtney A. Johnson, MPH (she/her/hers) – Brown University
### she/her/hers @@@ Theresa I. Shireman, PhD (she/her/hers) – Brown University ### 1658623###Author###Director Center for Gerontology & Health Care Research, Professor Health Services, Policy, &Practice###Brown University###Author: Theresa I. Shireman, PhD (she/her/hers) – Brown University
### she/her/hers @@@ Amal N. Trivedi, MD, MPH – Brown University ### 1900323###Author###Professor of Health Services, Policy & Practice, Professor of Medicine###Brown University###Author: Amal N. Trivedi, MD, MPH – Brown University
### @@@ Omar Galárraga, PhD (he/him/his) – Brown University ### 1900324###Author###Director of PhD Program in Health Services, Policy & Practice (HSPP), Associate Professor of HSPP###Brown University###Author: Omar Galárraga, PhD (he/him/his) – Brown University
### he/him/hisPresenting Author: Yasmin Elsobky, B.Pharm.SCi, MS (she/her/hers) – ALNAS Hospital
Author: Diane L. Seger, RPh (she/her/hers) – Brigham and Women's Hospital
Author: David Bates, MD (he/him/his) – Brigham and Women's Hospital
Comparative Effectiveness Research (CER)
Presenting Author: Yasmin Elsobky, B.Pharm.SCi, MS (she/her/hers) – ALNAS Hospital
### she/her/hers @@@ Diane L. Seger, RPh (she/her/hers) – Brigham and Women's Hospital ### 1359853###Author###Senior Pharmaco-Informatics Specialist###Brigham and Women's Hospital###Author: Diane L. Seger, RPh (she/her/hers) – Brigham and Women's Hospital
### she/her/hers @@@ David Bates, MD (he/him/his) – Brigham and Women's Hospital ### 1359858###Author###Chief, Division of General Internal Medicine and primary care###Brigham and Women's Hospital###Author: David Bates, MD (he/him/his) – Brigham and Women's Hospital
### he/him/hisPresenting Author: Grace (Hsin Min) Wang (she/her/hers) – University of Florida College of Pharmacy
Author: Scott Vouri (he/him/his) – Real World Evidence Internal Medicine, Pfizer
Author: Steven Smith (he/him/his) – Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA
Author: Wei-Hsuan Lo-Ciganic (she/her/hers) – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy
Geriatric Pharmacoepidemiology
Presenting Author: Grace (Hsin Min) Wang (she/her/hers) – University of Florida College of Pharmacy
### she/her/hers @@@ Scott Vouri (he/him/his) – Real World Evidence Internal Medicine, Pfizer ### 1900262###Author###Director###Real World Evidence Internal Medicine, Pfizer###Author: Scott Vouri (he/him/his) – Real World Evidence Internal Medicine, Pfizer
### he/him/his @@@ Steven Smith (he/him/his) – Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA ### 1900261###Author###Assistant professor###Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA###Author: Steven Smith (he/him/his) – Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA
### he/him/his @@@ Wei-Hsuan Lo-Ciganic (she/her/hers) – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy ### 1900260###Author###Associate Professor###Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy###Author: Wei-Hsuan Lo-Ciganic (she/her/hers) – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy
### she/her/hersModerator: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
Moderator: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
Author: Xiaomo Xiong, MS – College of Pharmacy, University of South Carolina
Author: Sam Li, PhD – University of Tennessee Health Science Center
Author: Xiaoxia Wang – University of South Carolina
Author: Gang Lv, MD – Chinese PLA General Hospital
Presenting Author: Kevin Lu, PhD, FISPE – University of South Carolina
Comparative Effectiveness Research (CER)
Author: Xiaomo Xiong, MS – College of Pharmacy, University of South Carolina
### @@@ Sam Li, PhD – University of Tennessee Health Science Center ### 1359863###Author###Assistant Professor###University of Tennessee Health Science Center###Author: Sam Li, PhD – University of Tennessee Health Science Center
### @@@ Xiaoxia Wang – University of South Carolina ### 1659234###Author###PharmD Student###University of South Carolina###Author: Xiaoxia Wang – University of South Carolina
### @@@ Gang Lv, MD – Chinese PLA General Hospital ### 1659238###Author###Deputy Chief Physician###Chinese PLA General Hospital###Author: Gang Lv, MD – Chinese PLA General Hospital
### @@@ Kevin Lu, PhD, FISPE – University of South Carolina ### 1093581###Presenting Author###Associate Professor###University of South Carolina###Presenting Author: Kevin Lu, PhD, FISPE – University of South Carolina
###Presenting Author: Oliver W. Scott, BHSc (first class hons) – University of Auckland
Author: Sandar TinTin, PhD – University of Auckland
Author: Sixten Harborg, PhD/MD student – Aarhus University
Author: Marion Kuper-Hommel, MD, FRACP, PhD – Waikato District Health Board
Author: Ross Lawrenson, MD – University of Waikato
Author: Mark Elwood, MD – University of Auckland
Cancer
Presenting Author: Oliver W. Scott, BHSc (first class hons) – University of Auckland
### @@@ Sandar TinTin, PhD – University of Auckland ### 1358076###Author###Senior Research Fellow###University of Auckland###Author: Sandar TinTin, PhD – University of Auckland
### @@@ Sixten Harborg, PhD/MD student – Aarhus University ### 1900223###Author###PhD student###Aarhus University###Author: Sixten Harborg, PhD/MD student – Aarhus University
### @@@ Marion Kuper-Hommel, MD, FRACP, PhD – Waikato District Health Board ### 1900224###Author###Oncologist###Waikato District Health Board###Author: Marion Kuper-Hommel, MD, FRACP, PhD – Waikato District Health Board
### @@@ Ross Lawrenson, MD – University of Waikato ### 1900225###Author###Professor in Population Health###University of Waikato###Author: Ross Lawrenson, MD – University of Waikato
### @@@ Mark Elwood, MD – University of Auckland ### 1358078###Author###Professor of Cancer Epidemiology###University of Auckland###Author: Mark Elwood, MD – University of Auckland
###